Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Argenx Se ADR
(NQ:
ARGX
)
516.69
-2.95 (-0.57%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Argenx Se ADR
< Previous
1
2
3
4
5
6
7
8
9
10
Next >
argenx Reports Positive Topline Data from ADHERE Study of VYVGART Hytrulo in Patients with Chronic Inflammatory Demyelinating Polyneuropathy
July 17, 2023
From
argenx SE
Via
GlobeNewswire
This Emerging Market Could Be the Next Big Thing in Biotech
July 14, 2023
Medicines to treat the many symptoms of long COVID are in high demand already.
Via
The Motley Fool
Week In Review: Billion Dollar Deals - Moderna’s Shanghai Investment And F-Star’s Takeda Collaboration
July 08, 2023
F-star Therapeutics formed a license agreement with Takeda to develop Fcab domains aimed at undisclosed immuno-oncology targets. Also, Brii Bio signed a global license to an HBV immunotherapeutic...
Via
Talk Markets
argenx and Zai Lab Announce Approval of VYVGART® (efgartigimod alfa injection) for Generalized Myasthenia Gravis in China
June 30, 2023
From
argenx SE
Via
GlobeNewswire
The Latest Analyst Ratings for argenx
June 07, 2023
Via
Benzinga
Analyst Expectations for argenx's Future
June 07, 2023
Via
Benzinga
Expert Ratings for argenx
May 31, 2023
Via
Benzinga
Analyst Ratings for argenx
April 21, 2023
Via
Benzinga
A Bearish Sign Appears On argenx's Chart
March 23, 2023
Via
Benzinga
Zai Lab and argenx Announce Approval of VYVGART® (efgartigimod alfa injection) for Generalized Myasthenia Gravis in China
June 30, 2023
From
Zai Lab Limited
Via
GlobeNewswire
FDA Approves Rystiggo: The Only Treatment for Two Most Common Subtypes of Generalized Myasthenia Gravis in Adults
June 27, 2023
The FDA approved UCB SA's (OTC: UCBJF) (OTC: UCBJY) Rystiggo (rozanolixizumab-noli) for generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AchR) or...
Via
Benzinga
AstraZeneca Seeks Expanded Use For Soliris As First Targeted Therapy For Pediatric Patients With Autoimmune Neuromuscular Disease
June 26, 2023
The European Union has reco
Via
Benzinga
Argenx's Vyvgart Hytrulo Becomes First FDA Approved Subcutaneous Option For Generalized Myasthenia Gravis
June 21, 2023
The FDA has approved Argenx SE's (NASDAQ: ARGX) Vyvgart Hytrulo (efgartigimod alfa and hyaluronidase-qvfc), an injection for subcutaneous (SC) use for generalized myasthenia gravis (gMG) in adult...
Via
Benzinga
Analyst Ratings for argenx
March 20, 2023
Via
Benzinga
Analyst Boosts Immunovant Price Target After Updated Pipeline Realignment
March 20, 2023
Via
Benzinga
argenx Announces U.S. Food and Drug Administration Approval of VYVGART Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) Injection for Subcutaneous Use in Generalized Myasthenia Gravis
June 20, 2023
From
argenx SE
Via
GlobeNewswire
10 Health Care Stocks With Whale Alerts In Today's Session
June 20, 2023
Via
Benzinga
argenx Initiates Second Cohort of Phase 2 ARDA Study of Empasiprubart in Multifocal Motor Neuropathy
June 20, 2023
From
argenx SE
Via
GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For May 31, 2023
May 31, 2023
Via
Benzinga
argenx to Present at Upcoming Investor Conferences
May 31, 2023
From
argenx SE
Via
GlobeNewswire
Booking Holdings To Rally Around 18%? Here Are 10 Other Analyst Forecasts For Friday
May 05, 2023
Wells Fargo raised the price target for Royal Caribbean Cruises Ltd. (NYSE: RCL) from $78 to $88. Wells Fargo analyst Daniel Politzer maintained an Overweight rating. Royal Caribbean Cruises shares...
Via
Benzinga
argenx Reports First Quarter 2023 Financial Results and Provides Business Update
May 04, 2023
From
argenx SE
Via
GlobeNewswire
argenx announces results of Annual General Meeting of Shareholders
May 03, 2023
From
argenx SE
Via
GlobeNewswire
argenx to Present at BofA Securities 2023 Health Care Conference
May 02, 2023
From
argenx SE
Via
GlobeNewswire
argenx to Report First Quarter 2023 Financial Results and Business Update on May 4, 2023
April 27, 2023
From
argenx SE
Via
GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For April 25, 2023
April 25, 2023
Via
Benzinga
7 Biotech Stocks That Could Cure Your Portfolio Woes
April 19, 2023
If you want to revitalize your portfolio with some exciting opportunities, these biotech stocks to buy might fit the bill.
Via
InvestorPlace
argenx Demonstrates Commitment to Redefining Treatment Goals for Generalized Myasthenia Gravis with Multiple Presentations at American Academy of Neurology 2023 Annual Meeting
April 18, 2023
From
argenx SE
Via
GlobeNewswire
argenx and Genmab Enter Partnership to Advance Antibody Therapies in Immunology and Oncology
April 17, 2023
From
argenx SE
Via
GlobeNewswire
10 Health Care Stocks With Whale Alerts In Today's Session
April 12, 2023
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
10
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.